AI Used to Identify 3 MS Subtypes
Source: Pixabay.com

AI Used to Identify 3 MS Subtypes

Currently, multiple sclerosis (MS), an autoimmune and neurological disorder, is considered either progressive or relapsing-remitting. But could there be additional subtypes? According to new research, yes. As explained in Medical…

Continue Reading AI Used to Identify 3 MS Subtypes
Cleveland Clinic Educational Seminar: Living with Chronic Disease
source: pixabay.com

Cleveland Clinic Educational Seminar: Living with Chronic Disease

On March 11, 2021, Patient Worthy attended an educational seminar hosted by the Cleveland Clinic titled Neuromyelitis Optica Spectrum Disorder (NMOSD): Educational Seminar for Patients, Family Members and Caregivers Focus…

Continue Reading Cleveland Clinic Educational Seminar: Living with Chronic Disease
New Multiple Sclerosis Drug Rejected by NICE
https://pixabay.com/en/denied-insurance-rejected-stamp-1936877/

New Multiple Sclerosis Drug Rejected by NICE

The National Institute for Health and Clinical Excellence (NICE), an agency under the UK's National Health Service (NHS), has recently rejected Zeposia. Zeposia is an oral, multiple sclerosis (MS) treatment…

Continue Reading New Multiple Sclerosis Drug Rejected by NICE
Experimental Treatment Reduces Retinal Thinning in Progressive Multiple Sclerosis
source: pixabay.com

Experimental Treatment Reduces Retinal Thinning in Progressive Multiple Sclerosis

According to a story from GlobeNewswire, the biopharmaceutical company MediciNova, Inc. has announced encouraging results related in Optical Coherence Tomography (OCT) in a phase 2b clinical trial. This clinical trial…

Continue Reading Experimental Treatment Reduces Retinal Thinning in Progressive Multiple Sclerosis

Why The FDA Cautions Rare Neurological Disease Patients About Dental Amalgams

In a press release from the FDA; the FDA has new recommendations for a common mercury-based filling, dental amalgams. While the mercury in the tooth treatment isn't significant enough to…

Continue Reading Why The FDA Cautions Rare Neurological Disease Patients About Dental Amalgams
Study Examines Telehealth Visits for Patients with Autoimmune Conditions During COVID-19
source: pixabay.com

Study Examines Telehealth Visits for Patients with Autoimmune Conditions During COVID-19

Michael George and his team from the University of Pennsylvania have recently uncovered new insights regarding autoimmune patient’s comfortability with care during COVID-19. They've been working since the pandemic began…

Continue Reading Study Examines Telehealth Visits for Patients with Autoimmune Conditions During COVID-19

Early Ocrelizumab Treatment Benefits Patients with Primary Progressive MS, Extension Study Shares

Did you know that there are multiple forms of multiple sclerosis (MS)? The most common form of MS is relapsing-remitting, meaning patients go through symptomatic periods and periods of remission.…

Continue Reading Early Ocrelizumab Treatment Benefits Patients with Primary Progressive MS, Extension Study Shares

Scientists Have Discovered An Immune Cell That May Partially Reverse Damage Caused by ALS and MS

A series of articles recently published in FierceBiotech describe a discovery by Ohio State and Michigan University scientists. The teams have discovered an immune cell that could be tapped to…

Continue Reading Scientists Have Discovered An Immune Cell That May Partially Reverse Damage Caused by ALS and MS

New Test Developed to Better Assess the Efficacy of Spinocerebellar Ataxia Type 3 Therapies

Researchers at the Mayo Clinic have collaborated with the international community to develop a potential way to test for spinocerebellar ataxia type 3 (SCA3), also called Machado-Joseph Disease. Additionally, they…

Continue Reading New Test Developed to Better Assess the Efficacy of Spinocerebellar Ataxia Type 3 Therapies
Enrollment for Phase 2 Amyotrophic Lateral Sclerosis Trial is Complete
source: pixabay.com

Enrollment for Phase 2 Amyotrophic Lateral Sclerosis Trial is Complete

According to a story from BioSpace, the biopharmaceutical company Clene Nanomedicine, Inc., has recently announced that it has completed the process of enrollment patient participants in its upcoming phase 2…

Continue Reading Enrollment for Phase 2 Amyotrophic Lateral Sclerosis Trial is Complete